Figure 2.
Kaplan-Meier time-to-event analysis of vedolizumab treatment persistence between inflammatory bowel disease patients with BMI <30 kg/m2 (dash) and BMI ≥30 kg/m2 (line)
BMI, body mass index
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.